Medical Advocates
Enfuvirtide [T-20] (Fuzeon)
 
Journal Citations

General Reports             Therapeutic Strategies
 In Vitro Data                   Patient Challenges
Diagnostics                     Quality of Life
 Safety                             Economics
 Pharmacokinetics          
Drug/Drug Interactions
 Viral Dynamics
 Resistance
 Adverse Events
 Efficacy

 
Enfuvirtide Main Page Main New/Newsworthy  Home Page      
Last updated:  December 23, 2011
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Perinatal Journal Data are in the Perinatal Data Page. Pediatric Journal Data are in the Pediatric Data Page
General Reports
 
 
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations.
 Dimonte S, Mercurio F, Svicher V, et al
Intervirology. 2011 Dec 21
 Abstract

Molecular dynamics simulations of T-20 HIV fusion inhibitor interacting with model membranes.
do Canto AM, Carvalho AJ, Ramalho JP, Loura LM
Biophys Chem. 2011 Aug 6.
 Abstract

Genotypic Analysis of the gp41 HR1 Region From HIV-1 isolates From Enfuvirtide-Treated
and Untreated Patients.
 Pessoa LS, Valadão AL, Abreu CM, et al
J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 3:S197-201.
Abstract

Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.
 Ashkenazi A, Wexler-Cohen Y, Shai Y.
Biochim Biophys Acta. 2011 Jul 5
 Abstract

FULL-TEXT ARTICLE
 A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 with high potency and stability.
 Pan C, Cai L, Lu H, Lu L, Jiang S.
J Biol Chem. 2011 Jun 20.
Paper

Enfuvirtide: from basic investigations to current clinical use.
 Joly V, Jidar K, Tatay M, Yeni P.
Expert Opin Pharmacother. 2010 Nov;11(16):2701-13.
 Abstract

Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide.
 Lou J, Smith RJ.
J Theor Biol. 2010 Sep 29
 Abstract

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive
enfuvirtide-containing antiretroviral therapy.
Gandhi RT, Bosch RJ, Aga E, et al 
J Infect Dis. 2010 Jan 15;201(2):293-6.
 Abstract

Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human
immunodeficiency virus type 1 activity.
Huet T, Kerbarh O, Schols D, Clayette P, et al 
Antimicrob Agents Chemother. 2010 Jan;54(1):134-42.
 Abstract
 
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists
McKinnell JA, Saag MS.
Curr Opin HIV AIDS. 2009 Nov;4(6):513-517.
 Abstract

Long-Lasting Enfuvirtide-Carrier Pentasaccharide Conjugates with Potent Anti-HIV-1 Activity.
Huet T, Kerbarh O, Schols D, Clayette P, et al
Antimicrob Agents Chemother. 2009 Oct 5.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Analysis of HIV Type 1 gp41 and Enfuvirtide Susceptibility among Men in the
United States Who Were HIV Infected Prior to Availability of HIV Entry Inhibitors.
 Hudelson SE, Marlowe N, Huang W, et al
AIDS Res Hum Retroviruses. 2009 Jun 24.
 Abstract

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed
patients.
 Viard JP, Fagard C, Chaix ML, et al  
AIDS. 2009 May 20
 Abstract

Enfuvirtide in HIV Patients: A Nursing Guideline for medication management.
Bigler S, Nicca D, Spirig R.
 Pflege. 2009 Feb;22(1):29-38
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced
HIV-infected patients: understanding physician and patient perspectives.
 Horne R, Cooper V, Fisher M.
AIDS Care. 2008 Oct;20(9):1029-38.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Reassessment of enfuvirtide's role in the management of HIV-1 infection.
 Marr P, Walmsley S 
Expert Opin Pharmacother. 2008 Sep;9(13):2349-62.
 Abstract
 
Specific Enfuvirtide-Associated Mutational Pathways In HIV-1 Gp41 Are Significantly
Correlated With an Increase in CD4(+) Cell Count, Despite Virological Failure.
 Svicher V, Aquaro S, D'Arrigo R, et al 
J Infect Dis. 2008 Apr 15
Abstract
 
Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.
 Mohanty U, Dixit NM. 
J Theor Biol. 2008 Apr 7;251(3):541-51.
 Abstract
 
Enfuvirtide antiretroviral therapy in HIV-1 infection.
Kitchen CM, Nuño M, Kitchen SG, Krogstad P, et al
 Ther Clin Risk Manag. 2008 Apr;4(2):433-9.
 Abstract
 
Enfuvirtide effects on human erythrocytes and lymphocytes functional properties.
 Vieira CR, Castanho M, Saldanha C, Santos NC. 
J Pept Sci. 2008 Jan 14
 Abstract
 
T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular
dynamics study.
 Martins Do Canto AM, Palace Carvalho AJ, Prates Ramalho JP, Loura LM. 
J Pept Sci. 2007 Dec 11
Abstract
 
CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility
of R5 HIV-1.
 Heredia A, Gilliam B, Devico A, et al 
AIDS. 2007 Jun;21(10):1317-22.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Spanish recommendations for proper use of enfuvirtide
 Ribera E, Moreno S, Viciana P, et al
Enferm Infecc Microbiol Clin. 2007 Feb;25(2):131-42.
 Abstract
 
A novel antiretroviral class (fusion inhibitors) in the management of HIV infection.
Present features and future perspectives of enfuvirtide (T-20).
 Manfredi R, Sabbatani S.  
 Curr Med Chem. 2006;13(20):2369-84.
Abstract
 
HIV-1 Coreceptor Use in Triple-Class Treatment-Experienced Patients: Baseline
Prevalence, Correlates, and Relationship to Enfuvirtide Response.
 Melby T, Despirito M, Demasi R,  
J Infect Dis. 2006 Jul 15;194(2):238-46.
 Abstract

Immunological Basis for IgE Hyper-Production in Enfuvirtide-Treated HIV- Positive Patients.
 Burastero SE, Paolucci C, Breda D, et al 
 J Clin Immunol. 2006 Apr 7;
 Abstract
 
Bioanalytical method development and validation for a large peptide HIV fusion inhibitor
(Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS.
 Chang D, Kolis SJ, Linderholm KH, et al 
Pharm Biomed Anal. 2005 Jul 1;38(3):487-96.
 Abstract
 
Enfuvirtide Is Active against HIV Type 1 Group O.
 Poveda E, Barreiro P, Rodes B, Soriano V. 
AIDS Res Hum Retroviruses. 2005 Jun;21(6):583-5
Abstract
 
Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced
HIV Disease.
 Sax PE, Losina E, Weinstein MC
 J Acquir Immune Defic Syndr. 2005 May 1;39(1):69-77
 Abstract
 
Enfuvirtide: the first HIV fusion inhibitor.
 Lazzarin A.  
Expert Opin Pharmacother. 2005 Mar;6(3):453-464.
 Abstract
 
Fuzeon, first of the so-called "fusion inhibitor" drug in new class of AIDS treatments and
its warnings
 Hayashi T
Nippon Rinsho. 2005 Jan;63(1):173-82.
 Abstract
 
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of
HIV-1-infected men.
Ghosn J, Chaix M-L, Peytavin G,
AIDS. 18(14):1958-1961, September 24, 2004.
Letter
 
Enfuvirtide
 Machala L. .
 Klin Mikrobiol Infekc Lek. 2004 Jun;10(3):114-117
 Abstract
 
Clinical management of treatment-experienced, HIV-infected patients with the fusion
inhibitor  enfuvirtide: consensus recommendations.
 Clotet B, Raffi F, Cooper D, et al.
AIDS. 2004 May 21;18(8):1137-1146.
 Abstract
 
Enfuvirtide: A fusion inhibitor for the treatment of HIV infection.
 Fung HB, Guo Y.
Clin Ther. 2004 Mar;26(3):352-78.
 Abstract
 
Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
 Hardy H, Skolnik PR 
Pharmacotherapy. 2004 Feb;24(2):198-211.
 Abstract
 
Enfuvirtide (Fuzeon): the first fusion inhibitor.
 Williams IG.
 Int J Clin Pract. 2003 Dec;57(10):890-7
 Abstract
Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection
Duffalo ML, James CW.
Ann Pharmacother. 2003 Oct;37(10):1448-56.
 Abstract
 
Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
Cervia JS, Smith MA. 
Clin Infect Dis. 2003 Oct 15;37(8):1102-6
 Abstract
 
In Vitro Data
 
 
Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide.
 Holguin A, Faudon JL, Labernardiere JL, Soriano V.
J Clin Virol. 2006 Dec 28;
Abstract
 
Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment
with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
 Su C, Melby T, Demasi R, Ravindran P, Heilek-Snyder G   .
J Clin Virol. 2006 Jun 7
 Abstract

Favorable Interactions between Enfuvirtide and 1-beta-D-2,6-Diaminopurine
Dioxolane In Vitro.
Tremblay CL, Poulin DL, Hicks JL, et al
Antimicrob Agents Chemother. 2003 Nov;47(11):3644-6.
 Abstract
Diagnostics
 
 
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development
in patients with virologic failure on enfuvirtide.
 Loutfy MR, Raboud JM, Montaner JS, et al
Antiviral Res. 2006 Dec 18;
 Abstract
 
Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting
Enfuvirtide (T-20) Resistance Mutations.
 Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR.  
J Clin Microbiol. 2006 Sep;44(9):3384-7.
 Abstract

Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors,
enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid
chromatography-tandem mass spectrometry.
van den Broek I, Sparidans RW, Huitema AD, et al
.J Chromatogr B Analyt Technol Biomed Life Sci 2006 May 16
 Abstract
 
An Improved HPLC Fluorimetric Method for the Determination of Enfuvirtide Plasma Levels in HIV-
Infected Patients.
 D'avolio A, de Requena MS, Ibanez A, et al 
Ther Drug Monit. 2006 Feb;28(1):110-115
 Abstract

Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide,
T-20) and its metabolite in human plasma using LC-MS/MS.
 Chang D, Kolis SJ, Linderholm KH, et al 
Pharm Biomed Anal. 2005 Jul 1;38(3):487-96
 Abstract
Safety
 
  Two-year safety and tolerability study of enfuvirtide use in salvage therapy of Thai HIV-1
experienced cases.
Prasithsirikul W, Hanvanich M, Suwanagool S,  et al
J Med Assoc Thai. 2011 Mar;94(3):303-8.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with
enfuvirtide in HIV-infected subjects.
 Thompson M, Dejesus E, Richmond G, et al 
AIDS. 2006 Feb 14;20(3):397-404.
 Abstract
 

A WEEK-IN-REVIEW FEATURED REPORT
Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in T
reatment-Experienced HIV-1-Infected Adults Over 48 Weeks.
Trottier B, Walmsley S, Reynes J, et al 
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-421.
 Abstract
 
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations
of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
 Wheeler DA, Lalezari JP, Kilby JM et al  
J Clin Virol. 2004 Jun;30(2):183-90
 Abstract

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous
enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
 Kilby JM, Lalezari JP, Eron JJ, et al.
AIDS Res Hum Retroviruses 2002 Jul 1;18(10):685-93
 Abstract
 
  A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based
antiretroviral therapy.
 Lalezari JP, Eron JJ, Carlson M, et al.
AIDS 2003 Mar 28;17(5):691-698
 Abstract
Pharmacokinetics
 
 
Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
 Price RW, Parham R, Kroll JL, et al  
Antivir Ther. 2008;13(3):369-74.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based
regimens in HIV-positive patients.
 Gonzalez de Requena D, Bonora S, Castagna A, et al
 J Antimicrob Chemother. 2008 May 16.
Abstract
 
Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.
 Mohanty U, Dixit NM.  
J Theor Biol. 2007 Dec 28
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Pharmacokinetic Bioequivalence of Enfuvirtide Using a Needle-Free Device versus Standard
Needle Administration.
 True AL, Chiu YY, Demasi RA, Stout R, Patel I.
Pharmacotherapy. 2006 Dec;26(12):1679-86.
Abstract
 
Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.
Stocker H, Kloft C, Plock N, et al
Antimicrob Agents Chemother. 2006 Feb;50(2):667-73.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with
enfuvirtide in HIV-infected subjects.
 Thompson M, Dejesus E, Richmond G, et al 
AIDS. 2006 Feb 14;20(3):397-404.
 Abstract
 
Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-
experienced human immunodeficiency virus type 1-infected patients.
 Mould DR, Zhang X, Nieforth K, et al 
Clin Pharmacol Ther. 2005 Jun;77(6):515-28
 Abstract
 
Enfuvirtide Binding Domain Is Highly Conserved in Non-B HIV Type 1 Strains from Cameroon,
West Central Africa.
 Aghokeng AF, Ewane L, Awazi B, et al   
AIDS Res Hum Retroviruses. 2005 May;21(5):430-3
 Abstract
 
Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide.
 Patel IH, Zhang X, Nieforth K, Salgo M, Buss N.
Clin Pharmacokinet. 2005;44(2):175-86.
 Abstract
 
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide
(T-20) in treatment-experienced HIV-1-infected patients.
 Wheeler DA, Lalezari JP, Kilby JM et al  
 J Clin Virol. 2004 Jun;30(2):183-90
 Abstract

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20),
a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
 Kilby JM, Lalezari JP, Eron JJ, et al.
AIDS Res Hum Retroviruses 2002 Jul 1;18(10):685-93
 Abstract
Drug/Drug Interactions
 
 
Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Férir G, Palmer KE, Schols D.
Virology. 2011 Jul 27
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Interaction Between Enfuvirtide, an Injectable Fusion Inhibitor, and Niacin in
an HIV-Infected Patient .
 Oates E, Dzintars K.
Ann Pharmacother. 2010 Nov 2
 Abstract

Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation
HIV-fusion inhibitors.
 Pan C, Lu H, Qi Z, Jiang S.
AIDS. 2009 Feb 24
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations
but not with increased hepatotoxicity: sub-analysis from RESIST.
 Raffi F, Battegay M, Rusconi S, et al 
AIDS. 2007 Sep;21(14):1977-1980.
 Abstract
 
Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of
Enfuvirtide (T-20) against R5 HIV-1 in vitro.
 Heredia A, Gilliam B, Latinovic O, et al 
Antimicrob Agents Chemother. 2007 May 7
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
 de Requena DG, Calcagno A, Bonora S, et al 
AIDS. 2006 Oct 3;20(15):1977-1979.
 Abstract
 
Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide.
 Patel IH, Zhang X, Nieforth K, Salgo M, Buss N.
Clin Pharmacokinet. 2005;44(2):175-86.
 Abstract
 
Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir-Boosted Saquinavir
in HIV-1-Infected Patients.
 Ruxrungtham K, Boyd M, Bellibas SE, et al    
 J Clin Pharmacol. 2004 Jul;44(7):793-803.
 Abstract
 
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency
virus type 1-infected patients.
 Zhang X, Lalezari JP, Badley AD, et al 
Clin Pharmacol Ther. 2004 Jun;75(6):558-68
 Abstract

Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide.
 Boyd MA, Zhang X, Dorr A, et al 
J Clin Pharmacol. 2003 Dec;43(12):1382-1391
 Abstract
Viral Dynamics
 
 
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
 Descamps D, Assoumou L, Masquelier B, et al 
J Antimicrob Chemother. 2008 Jun 13
 Abstract
 
Susceptibility of HIV Type 1 to the Fusion Inhibitor T-20 Is Reduced on Insertion of Host
Intercellular Adhesion Molecule 1 in the Virus Membrane.
 Beausejour Y, Tremblay MJ. 
J Infect Dis. 2004 Sep 1;190(5):894-902.
 Abstract
 
Immunological and virological study of enfuvirtide-treated HIV-positive patients.
 Barretina J, Blanco J, Bonjoch A, et al 
AIDS. 2004 Aug 20;18(12):1673-82.
Abstract
 
Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the
gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated
by gp120 Interactions with the Coreceptor.
 Derdeyn CA, Decker JM, Sfakianos JN, et al. .
 J Virol 2001 Sep;75(18):8605-8614
 Abstract

 Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses
interleukin-12 p70 production by humanmonocytes.
Braun MC, Wang JM, Lahey E, Rabin RL, Kelsall BL.
 Blood 2001 Jun 1;97(11):3531-3536
 Abstract

Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100
 Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS.
J Acquir Immune Defic Syndr 2000 Oct 1;25(2):99-102
 Abstract
Adverse Events
 
 
Subcutaneous Injection of the HIV-1 Fusion Inhibitor Enfuvirtide (FUZEON) May Result in Soft-Tissue
Accumulation of Tc-99m MDP.
 Pack LE, Zuckier LS.
Clin Nucl Med. 2012 Jan;37(1):100-1.
 Abstract

Enfuvirtide injection site reactions: A clinical and histopathological appraisal.
 Wallace BJ, Tan KB, Pett SL, et al.
Australas J Dermatol. 2011 Feb;52(1):19-26.
 Abstract

 A WEEK-IN-REVIEW FEATURED REPORT
The effects of enfuvirtide therapy on body composition and metabolic parameters
over 48 weeks in the TORO body imaging substudy.
 Cooper DA, Cordery DV, Reiss P, et al
HIV Med. 2010 May 17.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination
antiretroviral therapy?
Kousignian I, Launay O, Mayaud C, et al
J Antimicrob Chemother. 2009 Nov 10
 Abstract

A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
 Emerson CR, Post JJ, Workman C.
Int J STD AIDS. 2009 Apr;20(4):288-9.
 Abstract
 
Does Iatrogenic Scleroderma due to Injection-Site Reaction to Enfuvirtide Impair Absorption of
the Drug?
 Maggi P, Filotico R, Bonora S, et al 
Clin Drug Investig. 2008;28(5):305-11
 Abstract
 
Renal failure in a patient treated with atazanavir
Moddel M, Pfammatter R, Varga Z, Keusch G. 
Schweiz Rundsch Med Prax. 2006 Jun 7;95(23):949-51.
 Abstract
 
Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
 Leen C, Wat C, Nieforth K
Clin Infect Dis. 2004 Dec 1;39(11):e119-21.
 Abstract
 
Successful Desensitization to Enfuvirtide after a Hypersensitivity Reaction in an
HIV-1-Infected Man.
 Desimone JA, Ojha A, Pathak R, Cohn J.
Clin Infect Dis. 2004 Nov 15;39(10):e110-2.
 Abstract

Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
Ball RA, Kinchelow T.  
J Am Acad Dermatol. 2003 Nov;49(5):826-31
 Abstract
Resistance
 
 
FULL-TEXT ARTICLE
Impact of the HIV-1 env Genetic Context outside HR1-HR2 on Resistance to the Fusion Inhibitor
Enfuvirtide and Viral Infectivity in Clinical Isolates.
Baatz F, Nijhuis M, Lemaire M,  et al
PLoS One. 2011;6(7):e21535.
Paper
A WEEK-IN-REVIEW FEATURED REPORT
Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure
under salvage therapy.
 Charpentier C, Jenabian MA, Piketty C, et al
Scand J Infect Dis. 2011 May;43(5):373-9.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in
virological failure under salvage therapy.
 Charpentier C, Jenabian MA, Piketty C,  et al
Scand J Infect Dis. 2011 Feb 22
 Abstract

Baseline genotypic and phenotypic susceptibility of HIV-1 group O to enfuvirtide.
 Depatureaux A, Charpentier C, Collin G,  et al
Antimicrob Agents Chemother. 2010 Jun 14.
 Abstract

High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in
HIV-1-infected patients in Hong Kong.
Leung PH, Chen JH, Wong KH, et al
J Clin Virol. 2010 Mar;47(3):273-5.
 Abstract

High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in
HIV-1-infected patients in Hong Kong.
 Leung PH, Chen JH, Wong KH, et al 
J Clin Virol. 2010 Jan 27.
 Abstract

Therapy Failure following Selection of Enfuvirtide-Resistant HIV-1 in Cerebrospinal Fluid.
 van Lelyveld SF, Nijhuis M, Baatz F, et al
Clin Infect Dis. 2010 Jan 4.
 Abstract

High Level of Multidrug Resistance Mutations in HIV Type 1 pol Gene and Resistance-Associated
Mutations to Enfuvirtide (T-20) among Antiretroviral-Experienced Patients from Central Brazil.
Cardoso LP, de Araújo Stefani MM.  
AIDS Res Hum Retroviruses. 2009 Sep 30.
 Abstract

Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.
 Covens K, Kabeya K, Schrooten Y, et al
J Clin Virol. 2009 Feb 21.
 Abstract

Enfuvirtide (T-20) Resistance-Related Mutations in HIV Type 1 Subtypes B, C, and F Isolates from
Brazilian Patients Failing HAART.
 Oliveira AC, Martins AN, Pires AF, et al  
AIDS Res Hum Retroviruses. 2009 Feb;25(2):193-8.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
The Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations
in the HIV-1 Regulatory Protein Rev.
 Svicher V, Alteri C, D'Arrigo R, et al 
Antimicrob Agents Chemother. 2009 Jan 5.
 Abstract
 
Impact of the Enfuvirtide Resistance Mutation N43D and the Associated Baseline Polymorphism
E137K on Peptide Sensitivity and Six-Helix Bundle Structure.
 Bai X, Wilson KL, Seedorff JE, et al 
Biochemistry. 2008 May 29.
Abstract
 
Association between specific enfuvirtide resistance mutations and CD4 cell response during
enfuvirtide-based therapy.
 Melby TE, Despirito M, Demasi RA, et al  
AIDS. 2007 Nov 30;21(18):2537-9.
Abstract
 
Short Communication: Dynamics of Drug-Resistant HIV-1 in Plasma and Peripheral Blood
Cells in Patients during and after Enfuvirtide Therapy
 Poveda E, Briz V, Paraskevis D, et al
AIDS Res Hum Retroviruses. 2007 Sep;23(9):1078-1082.
 Abstract
 
Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1
infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.
 Morozov VA, Morozov AV, Schurmann D, et al 
Virus Genes. 2007 Apr 18;
Abstract
 
Interruption of Enfuvirtide in HIV-1-Infected Adults with Incomplete Viral Suppression on an
Enfuvirtide-Based Regimen.
 Deeks SG, Lu J, Hoh R, et al
J Infect Dis. 2007 Feb 1;195(3):387-91.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Increased Polymorphism in the HR-1 gp41 env Gene Encoding the Enfuvirtide (T20) Target in
HIV-1 Variants Harboring Multiple Antiretroviral Drug Resistance Mutations in the pol Gene.
 Si-Mohamed A, Piketty C, Tisserand P, et al
Acquir Immune Defic Syndr. 2006 Oct 30;
 Abstract
 
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected
patients receiving enfuvirtide treatment.
 Aquaro S, D'Arrigo R, Svicher V, et al 
J Antimicrob Chemother. 2006 Aug 5;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis
 .Lu J, Deeks SG, Hoh R,
 J Acquir Immune Defic Syndr. 2006 Jul 31;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to
Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2.
 Melby T, Sista P, Demasi R, et al
AIDS Res Hum Retroviruses. 2006 May;22(5):375-85
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected
with HIV-1.
 Perez-Alvarez L, Carmona R, Ocampo A, et al  
J Med Virol. 2005 Dec 21;78(2):141-147
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide
salvage therapy.
Poveda E, Rodes B, Lebel-Binay S, et al
J Clin Virol. 2005 Dec;34(4):295-301.
 Abstract
 
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope
function, entry inhibitor sensitivity, and virus neutralization.
 Reeves JD, Lee FH, Miamidian JL,et al 
J Virol. 2005 Apr;79(8):4991-9.
 Abstract
 
Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in
the gp41region of different HIV-1 genetic forms from T20 naive patients.
Carmona R, Perez-Alvarez L, Munoz M, et al
J Clin Virol. 2005 Mar;32(3):248-53
 Abstract
 
Emergence and evolution of enfuvirtide resistance following long-term therapy involves
heptad repeat 2 mutations within gp41.
Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA. et al  
Antimicrob Agents Chemother. 2005 Mar;49(3):1113-9.
 Abstract
 
Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during
Therapy with theT20 Fusion Inhibitor.
 Baldwin CE, Sanders RW, Deng Y, et al
J Virol. 2004 Nov;78(22):12428-37.
 Abstract
 
Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance
to Enfuvirtide during Long-Term Treatment.
 Menzo S, Castagna A, Monachetti A, et al
Antimicrob Agents Chemother. 2004 Sep;48(9):3253-9.
 Abstract
 
Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients
experiencing
prolonged virologic failure.
 Poveda E, Rodes B, Labernardiere JL, et a;  
J Med Virol. 2004 Sep;74(1):21-8.
 Abstract
 
Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML, Cammack N.
J Antimicrob Chemother. 2004 Jul 1
 Abstract
 
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant
to enfuvirtide (T-20).
 Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR.
 J Virol. 2004 May;78(9):4628-37.
Abstract
 
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or
safety of enfuvirtide.
Walmsley S, Henry K, Katlama C, et al.
J Infect Dis. 2003 Dec 15;188(12):1827-33
 Abstract

Uncommon Mutations at Residue Positions Critical for Enfuvirtide (T-20) Resistance in
Enfuvirtide-Naive Patients Infected With Subtype B and Non-B HIV-1 Strains.
 Roman F, Gonzalez D, Lambert C,  et al.
J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):134-9.
Abstract
   
  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving
Fusion Inhibitor (T-20) Monotherapy.
 Wei X, Decker JM, Liu H,
 Antimicrob Agents Chemother 2002 Jun;46(6):1896-1905
 Abstract
   
  FULL-TEXT ARTICLE
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived
inhibitory peptides.
Rimsky LT, Shugars DC, Matthews TJ.
J Virol 1998; 72(2):986-93.
Paper
Efficacy
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters:
a controlled pilot study.
 Bonora S, Calcagno A, Cometto C, et al
Infection. 2011 Dec 2.
Abstract

A WEEK IN REVIEW FEATURED REPORT
Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals.
 Elzi L, Kaufmann G, Weber R, et al
HIV Clin Trials. 2009 Jul 1;10(4):207-214.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure.
Cossarini F, Galli L, Sagnelli C, et al
 J Acquir Immune Defic Syndr. 2009 Apr 6
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Postmarketing Use of Enfuvirtide in Veterans: Provider Compliance with Criteria for Use, Overall
Efficacy, and Tolerability (November).
 Belperio PS, Mole LA, Halloran J, et al
Ann Pharmacother. 2008 Oct 21.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Safety and Efficacy of Enfuvirtide in Combination with Darunavir/Ritonavir and an Optimized
Background Regimen in Triple-Class Experienced HIV-Infected Patients: The BLQ Study.
 Dejesus E, Gottlieb MS, Gathe JC Jr, et al 
Antimicrob Agents Chemother. 2008 Sep 22
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing
in HIV-Infected Patients.
 Wright D, Rodriguez A, Godofsky E, et al 
HIV Clin Trials. 2008 Mar-Apr;9(2):73-82
 Abstract
 
Patients' Perception and Effectiveness of a Treatment Containing Enfuvirtide When Used in HIV-Infected
Patients Without Very Advanced Disease.
 Wright , Del Pozo , Fernández-Guerrero , et al 
HIV Clin Trials. 2008 Mar-Apr;9(2):83-90.
Abstract
 
Unexpected dramatic increase in CD4(+) cell count in a patient with AIDS after enfuvirtide
treatment despite persistent viremia and resistance mutations.
 Soria A, Cavarelli M, Sala S, et al  
J Med Virol. 2008 Apr 21;80(6):937-941
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients
Rachlis A, Angel J, Harris M, et al
Can J Infect Dis Med Microbiol. 2006 May;17(3):155-63.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Immunologic Benefits of Enfuvirtide in Patients Enrolled in a Drug Assistance Program (May).
 Saberi P, Caswell NH, Gruta CI, et al   
 Ann Pharmacother. 2008 Apr 15
Abstract
 
Adherence to Enfuvirtide and Its Impact on Treatment Efficacy.
 Rockstroh J, Dejesus E, Donatacci L, et al  
AIDS Res Hum Retroviruses. 2008 Feb
Abstract
 
The Safety and Efficacy of Enfuvirtide Therapy for HIV Infection in Patients with Hemophilia:
A Case Series.
 Polizzotto MN, Street AM, Wright E, et al 
Clin Infect Dis. 2007 Aug 15;45(4):e39-41.
 Abstract
 
Consensus Recommendation from a Group of German Experts for the Use of Enfuvirtide in
Heavily Pretreated HIV Patients.
 Salzberger B, Daumer M, Gute P, et al 
Eur J Med Res. 2007 Mar 26;12(3):93-102
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
 Bienvenu B, Krivine A, Rollot F, et al 
J  Med Virol. 2006 Aug 22;78(10):1312-1317
 Abstract
 
Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients
receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only
(TORO) trials.
 Raffi F, Katlama C, Saag M, et al  
Clin Infect Dis. 2006 Mar 15;42(6):870-7.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials.
Nelson M, Arasteh K, Clotet B, et al
 J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-412.
 Abstract
 
Sensitivity of HIV Type 1 Subtype C Isolates to the Entry Inhibitor T-20.
 Cilliers T, Patience T, Pillay C,et al
AIDS Res Hum Retroviruses. 2004 May;20(5):477-82.
 Abstract

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
 Lazzarin A, Clotet B, Cooper D, et al.  
 N Engl J Med 2003 May 29;348(22):2186-95
 Abstract
   
  FULL-TEXT PDF ARTICLE
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and
South America.
 Lalezari JP, Henry K, O'Hearn M, et al.
N Engl J Med 2003 Mar 13
 Paper
Therapeutic Strategies
 
 
Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure
under salvage therapy.
 Charpentier C, Jenabian MA, Piketty C, et al
Scand J Infect Dis. 2011 May;43(5):373-9.
 Abstract

Two-year safety and tolerability study of enfuvirtide use in salvage therapy of Thai HIV-1
experienced cases.
Prasithsirikul W, Hanvanich M, Suwanagool S,  et al
J Med Assoc Thai. 2011 Mar;94(3):303-8.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
The suppression of immune activation during enfuvirtide-based salvage therapy is
associated with reduced CCR5 expression and decreased concentrations of
circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up.
 Carsenti-Dellamonica H, Saïdi H, Ticchioni M, et al
HIV Med. 2010 May 24
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency
virus-infected patients shortly after liver transplantation.
 Teicher E, Abbara C, Duclos-Vallée JC, et al
Liver Transpl. 2009 Sep 29;15(10):1336-1342
 Abstract

Switching from a Toxicity-Causing Antiretroviral to Enfuvirtide in Patients with HIV:
The SWITCH TOX Study.
 Streinu-Cercel A, de Gorgolas M, Müller M, et al 
HIV Clin Trials. 2008 Jan 1;9(6):375-386
 Abstract
 
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide
was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients:
the INTENSE study.
 Clotet B, Capetti A, Soto-Ramirez LE, et al  
J Antimicrob Chemother. 2008 Sep 8
 Abstract
 
A report on the effect of commencing enfuvirtide on peripheral neuropathy.
 Cherry CL, Duncan AJ, Mackie KF, et al 
AIDS Res Hum Retroviruses. 2008 Aug;24(8):1027-30.
Abstract
 
Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure:
Results of a Pharmacokinetic Study of Enfuvirtide in HIV-1-Infected Patients With
Impaired Kidney Function.
 Tebas P, Bellos N, Lucasti C, et al 
J Acquir Immune Defic Syndr. 2007 Dec 13
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Interruption of Enfuvirtide in HIV-1-Infected Adults with Incomplete Viral Suppression on an
Enfuvirtide-Based Regimen.
 Deeks SG, Lu J, Hoh R, et al
 J Infect Dis. 2007 Feb 1;195(3):387-91.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced
patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
 Miro O, Garrabou G, Lopez S, et al  
Antivir Ther. 2006;11(5):625-30.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
 Bonjoch A, Negredo E, Puig J, et al
AIDS. 2006 Sep 11;20(14):1896-8.
 Abstract
 
Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase
inhibitor sparing regimen: the ALLIANCE Study.
 Dwyer DE, Workman C, Hales G, et al  
Antivir Ther. 2006;11(4):409-19.
 Abstract

Successful Desensitization to Enfuvirtide after a Hypersensitivity Reaction in an
HIV-1-Infected Man.
 Desimone JA, Ojha A, Pathak R, Cohn J.
Clin Infect Dis. 2004 Nov 15;39(10):e110-2.
 Abstract
Patient Challenges
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide.
 Lou J, Smith RJ.
J Theor Biol. 2010 Sep 29
 Abstract

Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced
HIV-infected patients: understanding physician and patient perspectives.
 Horne R, Cooper V, Fisher M.
AIDS Care. 2008 Oct;20(9):1029-38.
 Abstract
 
A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms
(the OPTIONS study).
Boyd MA, Truman M, Hales G,  et al
 Antivir Ther. 2008;13(3):449-53.
 Abstract
 
Patients' Perception and Effectiveness of a Treatment Containing Enfuvirtide When Used in HIV-Infected Patients
Without Very Advanced Disease.
 Wright , Del Pozo , Fernández-Guerrero , et al 
HIV Clin Trials. 2008 Mar-Apr;9(2):83-90
 Abstract
.
 A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetic Bioequivalence of Enfuvirtide Using a Needle-Free Device versus Standard
Needle Administration.
 True AL, Chiu YY, Demasi RA, Stout R, Patel I.
Pharmacotherapy. 2006 Dec;26(12):1679-86.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
 Rice C, Wilantewicz H.
AIDS Read. 2006 Sep;16(9):470-4, 490-1.
 Abstract
 
Quality of Life
 
  Health-Related Quality of Life With Enfuvirtide (ENF; T-20) in Combination With an
Optimized Background Regimen.
 Cohen CJ, Clumeck N, Molina JM, et al 
J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1140-1146.
 Abstract
Economics
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Cost-Effectiveness of Enfuvirtide in HIV Therapy for Treatment-Experienced Patients
in the United States.
 Hornberger J, Kilby JM, Wintfeld N, Green J.
AIDS Res Hum Retroviruses. 2006 Mar;22(3):240-7
 Abstract

Enfuvirtide Main Page Main New/Newsworthy  Home Page      

Enfuvirtide Journal Citations